Iron and Targeted Iron Therapy in Alzheimer’s Disease
-
Published:2023-11-15
Issue:22
Volume:24
Page:16353
-
ISSN:1422-0067
-
Container-title:International Journal of Molecular Sciences
-
language:en
-
Short-container-title:IJMS
Author:
Wang Jian1, Fu Jiaying1, Zhao Yuanxin1ORCID, Liu Qingqing1, Yan Xiaoyu1, Su Jing1ORCID
Affiliation:
1. Key Laboratory of Pathobiology, Department of Pathophysiology, Ministry of Education, College of Basic Medical Sciences, Jilin University, 126 Xinmin Street, Changchun 130012, China
Abstract
Alzheimer’s disease (AD) is the most common neurodegenerative disease worldwide. β-amyloid plaque (Aβ) deposition and hyperphosphorylated tau, as well as dysregulated energy metabolism in the brain, are key factors in the progression of AD. Many studies have observed abnormal iron accumulation in different regions of the AD brain, which is closely correlated with the clinical symptoms of AD; therefore, understanding the role of brain iron accumulation in the major pathological aspects of AD is critical for its treatment. This review discusses the main mechanisms and recent advances in the involvement of iron in the above pathological processes, including in iron-induced oxidative stress-dependent and non-dependent directions, summarizes the hypothesis that the iron-induced dysregulation of energy metabolism may be an initiating factor for AD, based on the available evidence, and further discusses the therapeutic perspectives of targeting iron.
Funder
National Natural Science Foundation of China Jilin Province Science and Technology Development Plan Project Jilin Province Health Science and Technology Ability Improvement Project Norman Bethune Project Plan of Jilin University
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference166 articles.
1. Alzheimer’s disease;Scheltens;Lancet,2021 2. Forecasting the global burden of Alzheimer’s disease;Brookmeyer;Alzheimers Dement.,2007 3. Andrade-Guerrero, J., Santiago-Balmaseda, A., Jeronimo-Aguilar, P., Vargas-Rodríguez, I., Cadena-Suárez, A.R., Sánchez-Garibay, C., Pozo-Molina, G., Méndez-Catalá, C.F., Cardenas-Aguayo, M.D., and Diaz-Cintra, S. (2023). Alzheimer’s Disease: An Updated Overview of Its Genetics. Int. J. Mol. Sci., 24. 4. Lanoiselée, H.M., Nicolas, G., Wallon, D., Rovelet-Lecrux, A., Lacour, M., Rousseau, S., Richard, A.C., Pasquier, F., Rollin-Sillaire, A., and Martinaud, O. (2017). APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases. PLoS Med., 14. 5. The genetic landscape of Alzheimer disease: Clinical implications and perspectives;Sleegers;Genet. Med.,2016
|
|